Core Viewpoint - The stock of Valiant Biopharma-B (09887) rose over 5% following the announcement of successful patient enrollment in a clinical study for its drug LBL-024, a dual-specific antibody targeting PD-L1 and 4-1BB, which is aimed at treating advanced melanoma and potentially lung neuroendocrine cancer [1] Company Developments - Valiant Biopharma announced the successful enrollment of the first patient in an Ib/II clinical study (NCT07099430) for LBL-024, which will explore its efficacy as a monotherapy or in combination for first-line treatment of advanced melanoma [1] - LBL-024 is noted as the first targeted therapy for the 4-1BB receptor to reach the registration clinical stage globally, with the potential to become the first approved drug for advanced lung neuroendocrine cancer [1] Industry Insights - CMB International released a report highlighting Valiant Biopharma's focus on developing immunotherapies involving immune checkpoint inhibitors and co-stimulatory agonists, while also expanding into other areas such as CD3T cell connectors and antibody-drug conjugates (ADC) [1] - The company has developed proprietary platforms, LeadsBody and X-body, which serve as engines for continuous drug discovery [1] - The report expresses optimism regarding Valiant Biopharma's development of PD-L1/4-1BB and TCE as next-generation immuno-oncology therapies [1]
维立志博-B午后涨超5% LBL-024黑色素瘤Ib/II期临床首例患者入组